News from janssen pharmaceuticals, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jul 14, 2014, 08:00 ET

Janssen Pharmaceuticals Seeks Expanded Label for Once-Monthly INVEGA® SUSTENNA® (paliperidone palmitate) to Show Delayed Time to Relapse Compared to Daily Oral Schizophrenia Therapies

 Janssen Pharmaceuticals, Inc. today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug...

Jun 18, 2014, 08:30 ET

Janssen Announces License Agreement With Vertex to Develop Novel Treatment for Influenza A

Janssen Pharmaceuticals, Inc. (Janssen) announced today that it has entered into an exclusive license agreement with Vertex Pharmaceuticals for...

May 13, 2014, 09:00 ET

Supplemental New Drug Applications for Once-Monthly Long-Acting Therapy INVEGA® SUSTENNA® (paliperidone palmitate) Submitted to the U.S. FDA for the Treatment of Schizoaffective Disorder

Janssen Pharmaceuticals, Inc., today announced the submission of supplemental New Drug Applications (sNDAs) for once-monthly atypical long-acting...

May 06, 2014, 16:00 ET
May 05, 2014, 09:00 ET
Apr 23, 2014, 08:00 ET

Debbie Allen, So You Think You Can Dance and Janssen Pharmaceuticals Create the T2 Dance Crew to Get People with Type 2 Diabetes Moving

 Emmy®-award winning actress and choreographer Debbie Allen, dancers from the hit televised dance competition So You Think You Can Dance,...

Apr 23, 2014, 08:00 ET

Debbie Allen, So You Think You Can Dance, y Janssen Pharmaceuticals crearon T2 Dance Crew para que las personas con Diabetes tipo 2 se pusieran en movimiento

 La coreógrafa y actriz ganadora del Emmy® Debbie Allen, bailarines de la exitosa competencia de baile televisada So You Think...

Apr 22, 2014, 09:00 ET

Janssen Pharmaceuticals, Inc. Announces Key Research Presentations at 167th Annual Meeting of the American Psychiatric Association

 Janssen Pharmaceuticals, Inc., and Janssen Research and Development, LLC, both members of the Johnson & Johnson Family of Companies,...

Mar 24, 2014, 08:00 ET
Janssen Logo.  (PRNewsFoto/Janssen Pharmaceutical Companies)

Janssen to Present New Simeprevir Data at The International Liver Congress™ 2014 of the European Association for the Study of the Liver (EASL)

 New data from the clinical development program for Janssen's protease inhibitor simeprevir in the treatment of genotype 1 chronic hepatitis C...

Jan 08, 2014, 18:17 ET

Janssen Pharmaceutical Companies of Johnson & Johnson Submit Citizen Petition to the U.S. FDA Regarding Naming of Biosimilars

Ask Agency to require that biosimilars bear distinguishable names to enhance patient safety The Janssen Pharmaceutical Companies of Johnson...

Oct 08, 2013, 08:00 ET

Janssen Acquires Investigational NS5A Inhibitor for the Treatment of Hepatitis C from GlaxoSmithKline

 Janssen Pharmaceuticals, Inc. (Janssen) announced today the acquisition of the investigational compound GSK2336805, an NS5a replication...

Sep 20, 2013, 08:45 ET

Pooled Analysis Confirms XARELTO® has Similar Efficacy and Reduces the Incidence of Major Bleeding by Nearly Half Compared to Standard of Care in Treatment of DVT and PE

Janssen Pharmaceuticals, Inc. (Janssen) announced today a newly published, pooled analysis of the Phase III EINSTEIN trial program, showing...

Apr 01, 2013, 17:55 ET

La FDA de EE. UU. aprueba INVOKANA™ (Canagliflozin) para el tratamiento de adultos con diabetes de tipo 2

Janssen Pharmaceuticals, Inc. anunció el viernes 29 de marzo que la Administración de Alimentos y Medicamentos de EE. UU....

Mar 29, 2013, 16:37 ET

U.S. FDA Approves INVOKANA™ (Canagliflozin) for the Treatment of Adults with Type 2 Diabetes

Janssen Pharmaceuticals, Inc. announced today the U.S. Food and Drug Administration (FDA) has approved INVOKANA™ (canagliflozin) for the...

Mar 14, 2013, 08:30 ET

Doctors Agree Small Lifestyle Changes Can Improve Outcomes of Patients with Type 2 Diabetes, National Survey Finds

 A new, national survey revealed physicians feel type 2 diabetes patients could better manage their disease by appreciating the benefits of...

Feb 05, 2013, 08:00 ET

XARELTO® to be Studied with Factor Xa Inhibitor Antidote

Janssen Pharmaceuticals, Inc. (Janssen) today announced a clinical collaboration agreement with Portola Pharmaceuticals, Inc. and Bayer HealthCare...

Nov 30, 2012, 09:47 ET

Janssen erklärt Absicht, Patente von Darunavir in ressourcenknappen Gegenden nicht durchzusetzen

- Die Strategie zielt auf die Unterstützung nachhaltiger Versorgung mit medizinisch vertretbarem, generischem Darunavir in Sub-Sahara-Afrika...

Nov 29, 2012, 16:28 ET

Janssen anuncia su intención de no imponer las patentes para darunavir en entornos con recursos limitados

- La política pretende apoyar el suministro sostenible de darunavir genérico médicamente aceptable en el África subsahariana...

Nov 29, 2012, 14:16 ET

Janssen annonce son intention de ne pas exécuter ses brevets sur le Darunavir dans les régions à ressources limitées

-- Une politique destinée à favoriser l'approvisionnement viable en Darunavir générique médicalement autorisé en...

Nov 29, 2012, 09:00 ET

Janssen Announces Intent Not to Enforce Patents for Darunavir in Resource-Limited Settings

 The Janssen Pharmaceutical Companies of Johnson & Johnson today announced their intention not to enforce the patents they own and control...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

Research and Markets